David Jorden
Chief Executive Officer at NUO THERAPEUTICS, INC.
Net worth: 2 M $ as of 29/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
James Gorman | M | 65 | 18 years | |
Peter Clausen | M | 58 | 16 years | |
Eric Grossman | M | 57 | 18 years | |
Frederick Pollock | M | 44 | 18 years | |
Scott Pittman | M | 65 | 8 years | |
Jon Alexander Schwartz | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | 19 years |
C. Winzer | M | 67 | 15 years | |
Gary Balkema | M | 69 | 8 years | |
Paul Mintz | M | 75 | 7 years | |
Bob Casale | M | 65 | 8 years | |
Pat Pace | M | 52 |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | 14 years |
Brian A. Pryor | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | - |
Glenn P. Goodrich | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | 19 years |
James Howland | M | - | 16 years | |
L. Blair Shamel | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | - |
Bradley Nyberg | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | - |
Taylor Henricks | M | - | 17 years | |
Kathy Bergsteinsson | F | - | 19 years | |
David Cook | M | - | 20 years | |
Frank Ducomble | M | - | 18 years | |
Jonathan Sessler | M | 68 |
The University of Texas at Austin
| 40 years |
Mandell Crawley | M | 48 | 20 years | |
Jonathan Starbecker | M | - | 18 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dean E. Tozer | M | 57 | 2 years | |
Jonathan Pruzan | M | 55 | 18 years | |
Steven Shallcross | M | 62 | 2 years | |
Thomas R. Nides | M | 63 | 5 years | |
Joe A. Del Guercio | M | 52 | 5 years | |
Natasha Giordano | F | 62 | 7 years | |
James S. Benson | M | 84 | 9 years | |
Andrew Scott Maslan | M | 54 | 8 years | |
Robert Scott | M | 78 | 2 years | |
Martin P. Rosendale | M | 66 | 7 years | |
Craig B. Mendelsohn | M | 69 | 3 years | |
Donald E. Moss | M | 79 |
The University of Texas at Austin
| 6 years |
Nadav Zohar | M | 59 | 7 years | |
Mayree Clark | F | 67 | 24 years | |
Carelyn P. Fylling | F | 76 | 17 years | |
Lawrence S. Atinsky | M | 55 | 4 years | |
Buddie Cloys Ballard | M | - |
The University of Texas at Austin
| 4 years |
John W. Hadden | M | 54 | 7 years | |
Jaye L. Thompson | M | 58 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 4 years |
Thomas Kelleher | M | 67 | 15 years | |
Ruth Porat | F | 66 | 12 years | |
Donald Healey | M | 62 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 7 years |
Randall W. Poston | M | - |
The University of Texas at Austin
| 5 years |
Stacy L. Brainin | F | - |
The University of Texas at Austin
| 7 years |
Vladislav Poshmorga | M | - | 4 years | |
Todd Taylor | M | - | 8 years | |
John Ghiselli | M | 60 |
The University of Texas at Austin
| 6 years |
Todd Schwarzinger | M | - | 9 years | |
Sean Willett | M | - | - | |
Thomas J. Murphy | M | - |
The University of Texas at Austin
| 5 years |
Laura A. Einspanier | F | - |
The University of Texas at Austin
| 8 years |
Allen H. Kupetz | M | - |
The University of Texas at Austin
| 3 years |
Kenny S. Frazier | M | - |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
Dame Amelia Fawcett | F | 67 | 16 years | |
James H. Stokes | M | 66 |
The University of Texas at Austin
| 7 years |
M. Connolly | M | 47 | 5 years | |
Diana Walters | F | 60 |
The University of Texas at Austin
| 5 years |
Jeffery D. Hildebrand | M | 64 |
The University of Texas at Austin
| 6 years |
Jaime Sanchez Yarza | M | - | - | |
Donald T. Nicolaisen | M | 79 | 11 years | |
Stephen Keith | M | 71 | 8 years | |
Carroll A. Reddic | M | 58 | 14 years | |
Lyle A. Hohnke | M | 80 | 3 years | |
Hutham Olayan | F | 69 | 15 years | |
Gerard Arpey | M | 65 |
The University of Texas at Austin
| 6 years |
Philip J. Purcell | M | 80 | 19 years | |
Patrick Paul Vanek | M | 68 | 5 years | |
Robert Wood Jones | M | 73 | 32 years | |
Seth Krauss | M | 53 | 3 years | |
Lynne Hohlfeld | F | 64 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 3 years |
Gary G. Lynch | M | 73 | 5 years | |
Lewis Little | M | 67 |
The University of Texas at Austin
| 6 years |
David Hung | M | 67 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 5 years |
Mark T. McLoughlin | M | 68 | 11 years | |
Howard Davies | M | 73 | - | |
Charles Phillips | M | 64 | 4 years | |
James R. McGlynn | M | - |
The University of Texas at Austin
| 7 years |
Jeff Lucado | M | - |
The University of Texas at Austin
| 6 years |
Rick S. Kent | M | 74 | 2 years | |
Brian L. Gerber | M | - |
The University of Texas at Austin
| 6 years |
Kirk Calhoun | M | 80 | - | |
Robert L. Hargett | M | - |
The University of Texas at Austin
| 7 years |
Eileen Murray | F | 66 | 2 years | |
Gail Maderis | F | 66 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 6 years |
Michael T. Segrest | M | - |
The University of Texas at Austin
| 6 years |
Gary W. Parr | M | 67 | 9 years | |
Fred Coulson | M | - | - | |
Roy J. Bostock | M | 83 | 8 years | |
Nelson Haight | M | 59 |
The University of Texas at Austin
| 5 years |
Alan D. Green | M | 59 |
The University of Texas at Austin
| 4 years |
Franklin Ruben | M | - |
The University of Texas at Austin
| 7 years |
Kenneth G. Hawari | M | 65 |
The University of Texas at Austin
| 4 years |
Karishma Chopra | F | - | 11 years | |
Jason Gellert | M | - | 5 years | |
Kay Cuclis | F | - |
The University of Texas at Austin
| 4 years |
James Head | M | 58 | 13 years | |
Jim Sherwin | M | - |
The University of Texas at Austin
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Jorden
- Personal Network